Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Core Insights - Silo Pharma is advancing its lead asset, SPC-15, towards first-in-human trials for PTSD, with a significant milestone being the completion of a large animal GLP study [2][10][11] - The company has partnered with AmplifyBio since 2022 to facilitate the development of SPC-15 through pre-clinical studies [2][6] - SPC-15 is an intranasal formulation that acts as a serotonin 4 receptor agonist, targeting PTSD and other stress-induced disorders [8][12] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on novel therapeutics for underserved conditions, including stress-induced psychiatric disorders and chronic pain [12] - The company is developing both traditional therapies and psychedelic treatments, with SPC-15 being its lead program [12] - Other programs include SP-26, a ketamine-loaded implant for fibromyalgia, and SPC-14, an intranasal compound for Alzheimer's disease [12] Research and Development - The upcoming GLP study will involve a 28-day repeat intranasal dosing regimen with a 14-day recovery period [7] - Previous studies have shown that SPC-15 has rapid absorption and good exposure over a 24-hour period, indicating a potential once-per-day dosing regimen for humans [7][8] - The company has submitted a pre-IND briefing package to the FDA, marking a step towards seeking IND approval for clinical trials [11]